Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCEANIC-AF phase 3 trial of asundexian versus apixaban in atrial fibrillation
MOH_2023-02-06_012299Phase 3Completed
- Sponsor
- Bayer
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of asundexian in Atrial fibrillation (AFib) (2 arms), sponsored by Bayer. Started Jan 2023; status: completed.
02
Drugs
asundexian
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on MOH_2023-02-06_012299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-02-06_012299.